Cencora

(New York Stock Exchange)
Back to all articles
Bullish +65

Cencora (COR) Q3 2026

AI-generated analysis

πŸ“ˆ Cencora reported Q3 2026 adjusted diluted EPS of $4.48, representing a 12.0% year-over-year increase.

πŸ’° Revenue reached $84.75 billion in the quarter, marking a 5.1% growth compared to the prior year.

πŸ† The company extended its streak of beating consensus EPS estimates to five consecutive quarters.

πŸ”¬ The February 2026 acquisition of OneOncology was the primary driver behind improved gross profit margins in U.S. Healthcare Solutions.

πŸ’΅ Gross profit margins for U.S. Healthcare Solutions expanded to 3.17% from 2.54% following the oncology integration.

πŸ“Š Segment operating income for U.S. Healthcare Solutions surged 15.9% to $966.18 million in Q3 2026.

πŸ’Έ Net interest expense increased 72.0% to $140.71 million due to $4.50 billion in debt raised for the OneOncology deal.

🌍 International operating income grew 20.8% driven by European distribution and global specialty logistics expansion.

πŸ’‰ Rising sales of GLP-1 products for diabetes and weight loss contributed to overall revenue strength.

πŸ“ˆ Management raised full-year fiscal 2026 adjusted diluted EPS guidance to a range of $17.75 to $17.95.

🎯 Full-year revenue is expected to grow between 4% and 6%, with operating income growth targeted at 13% to 14%.

πŸ’° A LIFO credit of $94.3 million was recorded in Q3 2026, compared to $52.1 million in the same quarter last year.

βš–οΈ The company recognized a $102.0 million reduction in opioid liability after dismissing related litigation.

πŸ“‰ Adjusted free cash flow is projected to be approximately $3.0 billion for fiscal 2026.

πŸ—οΈ Capital expenditures are expected to total approximately $900 million for the full year.

Bullish Signals
  • Cencora achieved a 12.0% year-over-year increase in adjusted diluted EPS to $4.48, demonstrating strong profitability growth.
  • Revenue grew by 5.1% to reach $84.75 billion, indicating robust top-line expansion across the business.
  • The acquisition of OneOncology successfully expanded U.S. Healthcare Solutions gross profit margins to 3.17%, improving overall efficiency.
  • Segment operating income in U.S. Healthcare Solutions increased by 15.9% to $966.18 million, reflecting successful integration.
  • International operations showed strong momentum with a 20.8% increase in operating income driven by European and global logistics growth.
  • Management raised full-year fiscal 2026 EPS guidance to $17.75-$17.95, signaling confidence in future performance.
  • The company secured a significant $102.0 million reduction in opioid liability following the dismissal of litigation, improving net position.
  • Projected adjusted free cash flow of $3.0 billion highlights strong liquidity generation capabilities for the fiscal year.
Risk Factors
  • Net interest expense rose sharply by 72.0% to $140.71 million due to $4.50 billion in debt incurred to finance the OneOncology acquisition.
  • The substantial increase in interest costs may pressure net income margins if revenue growth does not fully offset financing expenses.
Full Analysis
Cencora (COR) reported a robust fiscal third quarter for 2026, delivering adjusted diluted earnings per share of $4.48, a 12.0% year-over-year increase, and revenue of $84.75 billion, up 5.1%. This performance marks the fifth consecutive quarter where the company exceeded consensus EPS estimates, driven significantly by the February 2026 acquisition of OneOncology. The acquisition of OneOncology expanded U.S. Healthcare Solutions gross profit margins to 3.17% from 2.54% and boosted segment operating income by 15.9% to $966.18 million. While the deal necessitated raising debt to $4.50 billion, increasing net interest expense by 72.0% to $140.71 million, broader growth in specialty pharmaceutical distribution, rising GLP-1 sales, and international expansion offset these costs. Management raised its full-year fiscal 2026 adjusted diluted EPS guidance to a range of $17.75 to $17.95 and projected revenue growth between 4% and 6%. The company expects adjusted operating income to grow 13% to 14%, with specific targets set for U.S., International, and Other segments, signaling strong confidence in sustaining momentum through the fiscal year-end. Additional financial highlights include a LIFO credit of $94.3 million, a $102.0 million reduction in opioid liability following dismissed litigation, and projected adjusted free cash flow of approximately $3.0 billion against capital expenditures of roughly $900 million for the full year.